Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.